Plant ID: NPO30745
Plant Latin Name: Chrysanthemum morifolium
Taxonomy Genus: Chrysanthemum
Taxonomy Family: Asteraceae
NCBI TaxonomyDB:
n.a.
Plant-of-the-World-Online:
n.a.
China
NPSR1; | |
RECQL; TDP1; GLO1; ALOX12; CBR1; AKR1B1; HSD17B10; AKR1B10; NOX4; HSD17B1; TNKS; TNKS2; APEX1; POLB; | |
ACHE; | |
TOP2A; | |
PIM1; AXL; KDR; FLT3; CDK1; MAPK1; MET; CDK6; CDK8; IGF1R; AURKB; CSNK2A1; | |
CA12; CA7; CA4; | |
ESR2; | |
PHF8; | |
MMP12; | |
HIF1A; TP53; | |
LMNA; THPO; | |
XDH; | |
L3MBTL1; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | TNKS | Tankyrase-1 | O95271 | CHEMBL6164 |
Enzyme_unclassified | TNKS2 | Tankyrase-2 | Q9H2K2 | CHEMBL6154 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Isomerase | TOP2A | DNA topoisomerase II alpha | P11388 | CHEMBL1806 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Metallo protease | MMP12 | Matrix metalloproteinase 12 | P39900 | CHEMBL4393 |
Methyl-lysine/arginine binding protein | L3MBTL1 | Lethal(3)malignant brain tumor-like protein 1 | Q9Y468 | CHEMBL1287622 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Plant homeodomain | PHF8 | Histone lysine demethylase PHF8 | Q9UPP1 | CHEMBL1938212 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | CDK6 | Cyclin-dependent kinase 6 | Q00534 | CHEMBL2508 |
Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0019825; oxygen binding | 9.875E-10 | 1.792E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.713E-09 | 4.492E-06 | ALOX12, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, PHF8, XDH |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 5.848E-09 | 6.367E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 6.548E-08 | 3.395E-05 | AURKB, MAPK1, TNKS, TNKS2 |
BP | GO:0008283; cell proliferation | GO:0008284; positive regulation of cell proliferation | 9.192E-08 | 4.655E-05 | AKR1B1, ALOX12, CDK1, CDK6, CSNK2A1, FLT3, HIF1A, IGF1R, KDR, MAPK1, MMP12, PIM1, THPO |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.635E-07 | 6.676E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.411E-07 | 8.750E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 3.297E-07 | 1.158E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1 |
MF | GO:0005488; binding | GO:0020037; heme binding | 5.673E-07 | 1.669E-04 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, NOX4 |
MF | GO:0005488; binding | GO:0005524; ATP binding | 8.809E-07 | 2.316E-04 | AURKB, AXL, CDK1, CDK6, CDK8, CSNK2A1, FLT3, IGF1R, KDR, MAPK1, MET, PIM1, RECQL, TOP2A, TP53 |
BP | GO:0065007; biological regulation | GO:0032212; positive regulation of telomere maintenance via telomerase | 1.239E-06 | 2.932E-04 | AURKB, MAPK1, TNKS, TNKS2 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 5.548E-06 | 9.450E-04 | APEX1, POLB |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 5.637E-06 | 9.450E-04 | CA12, CA4, CA7 |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 5.685E-06 | 9.450E-04 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 6.756E-06 | 1.073E-03 | AURKB, CSNK2A1, FLT3, IGF1R, KDR, PIM1 |
MF | GO:0003824; catalytic activity | GO:0008353; RNA polymerase II carboxy-terminal domain kinase activity | 6.926E-06 | 1.085E-03 | CDK1, CDK8, MAPK1 |
BP | GO:0040011; locomotion | GO:0030335; positive regulation of cell migration | 8.587E-06 | 1.289E-03 | ALOX12, HIF1A, IGF1R, KDR, MAPK1, MET, NOX4, TP53 |
MF | GO:0003824; catalytic activity | GO:0016616; oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 9.135E-06 | 1.349E-03 | AKR1B1, AKR1B10, CBR1, HSD17B1, HSD17B10 |
BP | GO:0008152; metabolic process | GO:0070988; demethylation | 1.164E-05 | 1.625E-03 | APEX1, CYP1A1, CYP1A2, PHF8 |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 1.631E-05 | 2.114E-03 | CYP1A1, POLB, TP53 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.696E-05 | 2.160E-03 | CA12, CA4, CA7, ESR2, GLO1, L3MBTL1, MMP12, PHF8, TNKS, TP53 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 2.165E-05 | 2.719E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0042180; cellular ketone metabolic process | 2.173E-05 | 2.719E-03 | AKR1B1, AKR1B10, CYP19A1, GLO1 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 2.634E-05 | 3.204E-03 | AKR1B1, APEX1, AURKB, CDK1, CDK6, CDK8, CSNK2A1, ESR2, HIF1A, L3MBTL1, LMNA, MAPK1, PHF8, PIM1, POLB, RECQL, TNKS, TOP2A, TP53 |
BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 3.090E-05 | 3.697E-03 | ACHE, AKR1B1, AKR1B10, CBR1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0032502; developmental process | GO:0031100; animal organ regeneration | 3.186E-05 | 3.790E-03 | AXL, CDK1, CSNK2A1, FLT3 |
BP | GO:0008152; metabolic process | GO:0070213; protein auto-ADP-ribosylation | 3.319E-05 | 3.906E-03 | TNKS, TNKS2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.319E-05 | 3.906E-03 | CYP1A1, CYP1A2 |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 3.529E-05 | 4.088E-03 | CDK1, CSNK2A1, MAPK1, TNKS |
BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 4.050E-05 | 4.641E-03 | AKR1B1, CYP19A1, CYP1A2, NOX4, XDH |
BP | GO:0008152; metabolic process | GO:2000377; regulation of reactive oxygen species metabolic process | 4.955E-05 | 5.477E-03 | CYP1B1, HIF1A, NOX4, TP53, XDH |
BP | GO:0009987; cellular process | GO:0030154; cell differentiation | 5.078E-05 | 5.584E-03 | AXL, CBR1, CDK1, CDK6, CYP1A1, FLT3, GLO1, HIF1A, KDR, MAPK1, NOX4, THPO, TOP2A, TP53 |
BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 5.476E-05 | 5.962E-03 | CDK1, HIF1A, POLB, TNKS, TNKS2, TP53 |
BP | GO:0002376; immune system process | GO:0030097; hemopoiesis | 5.927E-05 | 6.389E-03 | FLT3, HIF1A, KDR, L3MBTL1 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 5.973E-05 | 6.407E-03 | CSNK2A1, HIF1A, KDR |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 7.182E-05 | 7.412E-03 | CYP19A1, CYP1A1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0018108; peptidyl-tyrosine phosphorylation | 7.808E-05 | 7.869E-03 | AXL, FLT3, IGF1R, KDR, MET |
MF | GO:0003824; catalytic activity | GO:0004693; cyclin-dependent protein serine/threonine kinase activity | 7.842E-05 | 7.869E-03 | CDK1, CDK6, CDK8 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 8.272E-05 | 8.263E-03 | CYP1A2, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 8.541E-05 | 8.378E-03 | CA12, CA4, CA7 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.009E-07 | 1.402E-05 | HSD17B1, CYP1A1, CYP1B1, CYP19A1, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 2.152E-07 | 1.496E-05 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 4.467E-07 | 2.070E-05 | FLT3, MAPK1, TP53, MET, HIF1A |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 5.981E-07 | 2.079E-05 | CDK6, MAPK1, TP53, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 6.783E-06 | 1.503E-04 | KDR, MAPK1, TP53, HIF1A, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.230E-06 | 3.420E-05 | CBR1, CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.496E-05 | 2.600E-04 | CDK6, MAPK1, TP53, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 3.162E-05 | 3.996E-04 | CDK6, FLT3, MAPK1, HIF1A, MET, TP53, IGF1R |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.373E-05 | 3.482E-04 | CBR1, CYP1A2, CYP1A1, CYP1B1 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04520 | Adherens junction | 2.505E-05 | 3.482E-04 | CSNK2A1, MAPK1, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 5.796E-05 | 6.197E-04 | CDK6, PIM1, CYP1B1, MAPK1, TP53, MET |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 8.806E-05 | 8.743E-04 | CBR1, AKR1B10, HSD17B1, CYP1A2, CYP1A1, AKR1B1, ALOX12, CYP2C19, CYP19A1, HSD17B10, XDH |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.050E-04 | 9.208E-04 | POLB, CDK6, CDK1, MAPK1, TP53 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 1.239E-04 | 1.013E-03 | CDK6, KDR, MAPK1, TP53, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 2.898E-04 | 2.234E-03 | CDK6, MAPK1, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 3.054E-04 | 2.234E-03 | FLT3, PIM1, MAPK1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.060E-04 | 9.208E-04 | CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 7.570E-06 | 1.503E-04 | CA12, CA4, CA7 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 3.916E-04 | 2.722E-03 | CBR1, ALOX12, CYP2C19 |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 4.708E-04 | 2.974E-03 | CDK6, MAPK1, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 4.708E-04 | 2.974E-03 | MAPK1, MET, HIF1A |
09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 6.327E-04 | 3.664E-03 | CDK6, MAPK1, TP53 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.183E-03 | 6.090E-03 | KDR, MAPK1, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 7.709E-04 | 4.286E-03 | FLT3, TP53, MET, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 1.389E-03 | 6.895E-03 | KDR, MAPK1, MET, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 1.126E-03 | 6.020E-03 | MAPK1, TP53, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 1.815E-03 | 8.140E-03 | KDR, MAPK1, MET, IGF1R |
09140 Cellular Processes | 09143 Cell growth and death | hsa04115 | p53 signaling pathway | 5.364E-04 | 3.242E-03 | CDK6, CDK1, TP53 |
09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.486E-03 | 7.125E-03 | CDK1, MAPK1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.715E-03 | 7.944E-03 | MAPK1, HIF1A, IGF1R |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 2.178E-03 | 8.650E-03 | MAPK1, ALOX12, CYP2C19 |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.526E-03 | 9.491E-03 | MAPK1, TP53, HIF1A |
09160 Human Diseases | 09161 Cancers | hsa05216 | Thyroid cancer | 2.020E-03 | 8.507E-03 | MAPK1, TP53 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 2.161E-03 | 8.650E-03 | AKR1B10, AKR1B1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.020E-03 | 8.507E-03 | CYP1A2, CYP2C19 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00051 | Fructose and mannose metabolism | 2.457E-03 | 9.485E-03 | AKR1B10, AKR1B1 |
09120 Genetic Information Processing | 09124 Replication and repair | hsa03410 | Base excision repair | 2.611E-03 | 9.552E-03 | POLB, APEX1 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 5.153E-05 | 5.968E-04 | CYP1A2, XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; TP53; |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | MMP12; CBR1; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MMP12; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | IGF1R; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MMP12; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; AKR1B1; TP53; |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
NA: NA | GIST | NA | FLT3; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; XDH; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
C00-D49: Neoplasms | Breast cancer | C50 | CDK1; IGF1R; KDR; FLT3; CYP19A1; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; |
C00-D49: Neoplasms | Cancer | C00-C96 | PIM1; MET; CDK1; IGF1R; KDR; CSNK2A1; FLT3; ACHE; HIF1A; MAPK1; TP53; |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | MMP12; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
C00-D49: Neoplasms | Prostate cancer | C61 | FLT3; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
I00-I99: Diseases of the circulatory system | Aortic aneurysm | I71 | MMP12; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | TOP2A; MET; AURKB; IGF1R; KDR; FLT3; HIF1A; MAPK1; TP53; |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; TP53; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | CDK1; IGF1R; ACHE; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | NPSR1; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; TP53; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Leukemia | C90-C95 | FLT3; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |